Information Provided By:
Fly News Breaks for January 26, 2018
ZYNE
Jan 26, 2018 | 10:33 EDT
Seaport Global analyst Corey Davis initiated Zynerba with a Buy and $16 price target. The analyst is positive on management's quick decision to redesign ZYN002, or cannabidiol, following the two failures last year in epilepsy and osteoarthritis pain, saying there are still reasons to believe that cannabidiol will have utility in multiple indications as the company has identified a more refined patient population for a new study in adults with refractory epilepsy. This corrects a prior note regarding the reasons for the analyst's rating.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.